Our NCL is a “hit finding library” including most of the best published kinase inhibitors and several proprietary structures. NCL contains more than 12,000 compounds, 108 core structures and more than 300 scaffolds with proven kinase inhibitory activity on various kinase targets. We have inhibitors against 124 kinases.

 

Based on our NCL/Master Key/Scaffold hopping techniques, our partner selects a kinase target, we set up the biochemical kinase assay, and in a year we deliver a novel patentable, submicromolar kinase inhibitory lead structure.